Semaglutide + BPC-157 Calculator
Semaglutide for weight management paired with BPC-157 to support gastrointestinal comfort and tissue health during the dose escalation phase.
Syringe Size
Which syringe will you use? (applies to all peptides below)
Semaglutide
Weekly GLP-1 agonist (weight management)
Vial Size
BAC Water
Dose per Injection
Concentration
2.5 mg/mL
Volume
0.200 mL
Draw to
20.0 IU
Doses / vial
10
BPC-157
Daily GI mucosal support
Vial Size
BAC Water
Dose per Injection
Concentration
2.5 mg/mL
Volume
0.100 mL
Draw to
10.0 IU
Doses / vial
20
Stack Overview
What You'll Need
Step-by-Step Guide
Follow these steps in order. Each step assumes you have no prior experience. Read each one fully before doing it.
These two peptides are NOT injected together. Semaglutide is injected once per week on the same day each week (e.g. every Monday morning). BPC-157 is injected every day, typically in the morning. Keep both schedules consistent — semaglutide's GLP-1 mechanism relies on stable weekly dosing, and BPC-157's GI protective effects are best maintained with daily administration.
Wash your hands. Swab the tops of the semaglutide vial and bacteriostatic water vial with alcohol swabs. Let dry for 15 seconds. Draw the calculated volume of bacteriostatic water and inject it slowly down the glass wall of the semaglutide vial. Wait 60–90 seconds, then gently swirl — never shake — until the powder fully dissolves. The solution should be clear or very slightly yellow. Label the vial with today's date. One reconstituted vial provides multiple weekly doses.
Follow the same process for BPC-157: swab the vial top, inject bacteriostatic water slowly down the glass wall, wait 60 seconds, gently swirl. Label with today's date. A 5 mg vial with 2 mL of bacteriostatic water gives 2,500 mcg/mL — a 250 mcg dose is just 0.10 mL (10 IU), making daily dosing from one vial practical for 20 doses.
Every week on the same day: draw your semaglutide dose (see calculator for your exact IU). Inject subcutaneously into the abdomen, upper thigh, or upper arm. Rotate sites — don't use the same spot two weeks in a row. The semaglutide injection itself may cause mild stinging; injecting slowly over 10–15 seconds reduces this.
Each morning, draw your BPC-157 dose from the reconstituted vial. A 250 mcg dose at 2,500 mcg/mL concentration is 0.10 mL (10 IU) — a very small volume. Inject subcutaneously into the abdomen. This injection is quick because the volume is small. Rotate your injection site daily to different areas of the abdomen.
GI side effects from semaglutide are most pronounced in the 1–3 days following each weekly injection and tend to improve as the body adjusts. Helpful strategies: eat smaller meals more frequently; avoid high-fat, spicy, or strong-smelling foods in the 24 hours after injection; stay well hydrated; inject in the evening rather than morning if daytime nausea is a problem. The BPC-157 in this protocol is included specifically to support GI comfort during this period.
Both reconstituted vials must be stored in the refrigerator at 2–8°C. Semaglutide is particularly sensitive to temperature — never leave it at room temperature for more than a few minutes. When traveling, use a small insulated medication cooler. Discard both vials 28 days after reconstitution, regardless of remaining volume.
Dosing Schedule
Semaglutide escalation (standard STEP trial protocol):
Weeks 1–4: 0.25 mg (250 mcg) subcutaneously once weekly
Weeks 5–8: 0.5 mg (500 mcg) subcutaneously once weekly
Weeks 9–12: 1.0 mg (1,000 mcg) subcutaneously once weekly
Weeks 13–16: 1.7 mg (1,700 mcg) subcutaneously once weekly
Week 17+: 2.4 mg (2,400 mcg) subcutaneously once weekly (maintenance)
BPC-157 (continuous throughout):
250–500 mcg subcutaneously every morning
Note: Each escalation step can be extended by 4 additional weeks if GI tolerability is a concern.
Why These Peptides Are Combined
Semaglutide produces GLP-1 receptor-mediated weight loss through reduced appetite, delayed gastric emptying, and improved insulin sensitivity. However, the GI side effects — nausea, vomiting, reflux, and slowed gastric motility — are the most common reason research subjects discontinue or cannot tolerate dose escalation.
BPC-157 has a well-documented gastroprotective profile in animal research, with demonstrated effects on gastric mucosal healing, reduction of gastric lesions, and cytoprotective actions on the GI lining. It has been shown to counteract NSAID-induced gut injury, alcohol-induced gut damage, and stress-induced mucosal injury in multiple rodent models. The gastric juice protein from which BPC-157 is derived originally attracted attention precisely because of its cytoprotective role in the stomach lining.
The rationale for combining them is straightforward: BPC-157's GI protective actions may mitigate the gastric discomfort and mucosal irritation that contribute to semaglutide's GI side effects, allowing the dose escalation schedule to be followed more comfortably in research settings. BPC-157 does not interfere with semaglutide's GLP-1 receptor mechanism.
Note that these two peptides have very different dosing frequencies and timing — they are not injected together but rather on separate schedules.
